Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An update on ASTRAL-3: guadecitabine vs treatment of choice in adults with previously treated MDS

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of the Phase III ASTRAL-3 trial comparing guadecitabine versus treatment of choice in adults with myelodysplastic syndromes (MDS) previously treated with hypomethylating agents (HMAs) (NCT02907359). Despite promising pre-clinical efficacy, the study did not report a significant improvement in overall survival (OS) for patients treated with guadecitabine. Dr Garcia Manero explains that this study should be used to improve the design of new Phase III studies in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.